Home Ingredients genVida® (non-soy genistein)
Women's HealthMenopause SupportBone Health

genVida® (non-soy genistein)

Genistein (chemically and biotechnologically produced)
Evidence Level
Moderate
2 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

genVida® is a branded non-soy form of pure genistein produced by DSM that delivers the same isoflavone phytoestrogen studied in landmark trials of soy-derived genistein—without the soy protein matrix. It is positioned for menopause, bone, and women's health formulations where a soy-free, allergen-friendly source of standardized genistein aglycone is desired. The branded ingredient leans on the broader genistein literature, including 12- to 24-month randomized trials in osteopenic postmenopausal women using approximately 54 mg per day that demonstrated improvements in bone mineral density, hot flash frequency, quality of life, and select cardiovascular risk markers. genVida is best understood as a delivery and sourcing innovation around the same molecule.

Studied Dose Genistein clinical literature most commonly uses 54 mg per day of the aglycone for 6–24 months; genVida is typically formulated to deliver similar genistein aglycone amounts.
Active Compound Pharmaceutical-grade genistein aglycone delivered as a non-soy branded ingredient.

Benefits

Supports bone health in postmenopausal women

As a source of pure genistein aglycone, genVida draws on randomized controlled trial evidence showing 54 mg per day for 24 months can support bone mineral density and bone turnover markers in osteopenic postmenopausal women.

Supported by Trial 1, Trial 2

Helps reduce menopausal hot flashes

Daily genistein supplementation has been associated in placebo-controlled trials with progressive reductions in hot flash frequency over 3 to 12 months, supporting comfort during the menopausal transition.

Supported by Trial 2

Provides a soy-free isoflavone source

As a non-soy genistein ingredient, genVida supplies standardized phytoestrogen activity for consumers and formulators who prefer to avoid soy due to allergies, sensitivities, or formulation preferences.

Supported by Trial 1, Trial 2

Supports menopausal quality of life

Long-term genistein trials in postmenopausal women have shown improvements in quality-of-life and self-reported mood measures alongside skeletal endpoints, supporting overall well-being during the menopausal transition.

Supported by Trial 2, Trial 1

Mechanism of action

1

Selective ER-beta agonism

Like soy-derived genistein, genVida-delivered genistein preferentially activates estrogen receptor beta over ER-alpha, producing tissue-selective phytoestrogen effects in bone, vasculature, and central thermoregulatory pathways.

2

Modulation of bone remodeling

Genistein supports osteoblast differentiation and reduces osteoclast-mediated bone resorption through ER-beta-mediated signaling, contributing to gains in bone mineral density observed in long-term trials.

3

Antioxidant and signaling modulation

Genistein scavenges reactive oxygen species, inhibits select tyrosine kinases, and modulates inflammatory pathways relevant to cardiovascular and metabolic health alongside its phytoestrogenic activity.

Clinical trials

1
24-month bone density RCT (parent compound)

Multicenter RCT of 54 mg/day genistein aglycone vs placebo for 24 months with calcium and vitamin D in both arms.

389 osteopenic postmenopausal women.

Genistein recipients showed BMD increases at the lumbar spine and femoral neck while placebo recipients showed decreases, with favorable changes in bone turnover markers. Findings are directly applicable to the same dose of genistein delivered via genVida.

2
12-month hot flush RCT (parent compound)

Randomized, double-blind, EPT- and placebo-controlled study; 54 mg/day genistein for 12 months.

90 early postmenopausal women aged 47–57.

Daily flushes reduced significantly versus placebo by 22% at 3 months, 29% at 6 months, and 24% at 12 months in the genistein group, providing direct support for use of pure genistein—the active in genVida—for menopausal vasomotor symptoms.

Side effects and drug interactions

Common Potential side effects

Mild gastrointestinal complaints such as bloating, gas, or constipation can occur.
Breast tenderness has been reported infrequently with phytoestrogen use.
Headache or transient discomfort may occur in sensitive individuals.
Theoretical caution remains about high-dose use in hormone-sensitive cancers.

Important Drug interactions

May interact with tamoxifen and aromatase inhibitors via estrogen receptor activity.
Theoretical interaction with thyroid hormone replacement; separate dosing recommended.
May affect anticoagulant response; INR monitoring is reasonable with warfarin.
Could compound effects of hormone replacement therapy or oral contraceptives.

More Women's Health Ingredients

Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Cognitive
Vitamin B6 (Pyridoxine)
Vitamin B6 (pyridoxine) is a water-soluble vitamin essential for amino acid metabolism, ne…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a naturally occurring sugar alcohol that acts as a secondary messenger in insu…
Mood & Mental Health
Saffron Extract (Crocus sativus)
Saffron is the dried stigmas of Crocus sativus — the most expensive spice in the world by…

Frequently asked questions about genVida® (non-soy genistein)

What is the recommended dosage of genVida® (non-soy genistein)?

The clinically studied dose for genVida® (non-soy genistein) is Genistein clinical literature most commonly uses 54 mg per day of the aglycone for 6–24 months; genVida is typically formulated to deliver similar genistein aglycone amounts.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is genVida® (non-soy genistein) used for?

genVida® (non-soy genistein) is studied for supports bone health in postmenopausal women, helps reduce menopausal hot flashes, provides a soy-free isoflavone source. As a source of pure genistein aglycone, genVida draws on randomized controlled trial evidence showing 54 mg per day for 24 months can support bone mineral density and bone turnover markers in osteopenic postmenopausal women.

Are there side effects from taking genVida® (non-soy genistein)?

Reported potential side effects may include: Mild gastrointestinal complaints such as bloating, gas, or constipation can occur. Breast tenderness has been reported infrequently with phytoestrogen use. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does genVida® (non-soy genistein) interact with medications?

Known drug interactions may include: May interact with tamoxifen and aromatase inhibitors via estrogen receptor activity. Theoretical interaction with thyroid hormone replacement; separate dosing recommended. Consult a pharmacist or healthcare provider if you take prescription medications.

Is genVida® (non-soy genistein) good for women's health?

Yes, genVida® (non-soy genistein) is researched for Women's Health support. As a source of pure genistein aglycone, genVida draws on randomized controlled trial evidence showing 54 mg per day for 24 months can support bone mineral density and bone turnover markers in osteopenic postmenopausal women.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Annals of Internal Medicine. 2007;Ann Intern Med. 2007 Jun 19;146(12):839-47..PubMedUsed to support: Pivotal 24-month bone density RCT for the genistein molecule delivered by genVida.
  2. Crisafulli A, Marini H, Bitto A, Altavilla D, Squadrito G, Romeo A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004;Menopause. 2004 Jul-Aug;11(4):400-4..PubMedUsed to support: 12-month hot flush RCT for the same genistein active delivered by genVida.